
Interim phase III results showed a significant reduction at 37 weeks, while the study continues to track kidney function.
Roche said its investigational drug sefaxersen reduced proteinuria by 43.1% versus placebo after 37 weeks in an interim analysis of a phase III trial in people with IgA nephropathy. The reduction was statistically significant, the company said.
Treatment effects were consistent across all prespecified patient subgroups. Roche said the drug’s safety profile matched results from an earlier phase II study, with no new safety signals.
The study will continue to assess kidney function over two years, with results measured at week 105. Sefaxersen is designed as a once-monthly injection under the skin that patients can administer at home.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.